- Home
- USEA vs EVAX Comparison
USEA vs EVAX Comparison
Compare USEA & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- EVAX
- Stock Information
- Founded
- USEA 2004
- EVAX 2008
- Country
- USEA Greece
- EVAX Denmark
- Employees
- USEA N/A
- EVAX N/A
- Industry
- USEA Marine Transportation
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USEA Consumer Discretionary
- EVAX Health Care
- Exchange
- USEA Nasdaq
- EVAX Nasdaq
- Market Cap
- USEA 15.6M
- EVAX 17.8M
- IPO Year
- USEA N/A
- EVAX 2021
- Fundamental
- Price
- USEA $1.70
- EVAX $2.94
- Analyst Decision
- USEA
- EVAX Strong Buy
- Analyst Count
- USEA 0
- EVAX 2
- Target Price
- USEA N/A
- EVAX $10.00
- AVG Volume (30 Days)
- USEA 22.5K
- EVAX 89.3K
- Earning Date
- USEA 08-06-2025
- EVAX 10-30-2025
- Dividend Yield
- USEA 2.35%
- EVAX N/A
- EPS Growth
- USEA N/A
- EVAX N/A
- EPS
- USEA N/A
- EVAX N/A
- Revenue
- USEA $42,625,000.00
- EVAX $3,176,000.00
- Revenue This Year
- USEA N/A
- EVAX N/A
- Revenue Next Year
- USEA N/A
- EVAX N/A
- P/E Ratio
- USEA N/A
- EVAX N/A
- Revenue Growth
- USEA N/A
- EVAX 1042.45
- 52 Week Low
- USEA $1.00
- EVAX $1.20
- 52 Week High
- USEA $2.78
- EVAX $17.20
- Technical
- Relative Strength Index (RSI)
- USEA 61.69
- EVAX 52.59
- Support Level
- USEA $1.66
- EVAX $2.71
- Resistance Level
- USEA $1.78
- EVAX $3.04
- Average True Range (ATR)
- USEA 0.05
- EVAX 0.19
- MACD
- USEA 0.00
- EVAX -0.02
- Stochastic Oscillator
- USEA 63.64
- EVAX 57.53
About USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of seven dry bulk vessels, comprising three Panamax, two Capesize and two Kamsarmax vessels with an aggregate cargo-carrying capacity of approximately 750,758 dwt.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.